X4 PHARMACEUTICALS, INC.
955 Massachusetts Avenue, 4th Floor
Cambridge, MA 02139
August 27, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
Justin Dobbie
| RE: | X4 Pharmaceuticals, Inc. |
Registration Statement on Form S-3
File No. 333-233161
Acceleration Request
Requested Date: August 29, 2019
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-233161) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Thursday, August 29, 2019, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.
[Signature page follows]
| Sincerely,
X4 PHARMACEUTICALS, INC. | ||
| By: | /s/ Adam S. Mostafa | |
| Adam S. Mostafa | ||
| Chief Financial Officer | ||
| cc: | Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc. |
Daniel I. Goldberg, Cooley LLP
Courtney T. Thorne, Cooley LLP